<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-213 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-213</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-213</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-5.html">extraction-schema-5</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation prevalence in lung cancer across different ethnic populations, particularly comparing East Asian and non-Asian populations, including frequencies, patient characteristics, environmental factors, and proposed explanations for ethnic differences.</div>
                <p><strong>Paper ID:</strong> paper-231595927</p>
                <p><strong>Paper Title:</strong> Molecular Epidemiology of the Main Druggable Genetic Alterations in Non-Small Cell Lung Cancer</p>
                <p><strong>Paper Abstract:</strong> Lung cancer is the leading cause of death for malignancy worldwide. Its molecular profiling has enriched our understanding of cancer initiation and progression and has become fundamental to provide guidance on treatment with targeted therapies. Testing the presence of driver mutations in specific genes in lung tumors has thus radically changed the clinical management and outcomes of the disease. Numerous studies performed with traditional sequencing methods have investigated the occurrence of such mutations in lung cancer, and new insights regarding their frequency and clinical significance are continuously provided with the use of last generation sequencing technologies. In this review, we discuss the molecular epidemiology of the main druggable genetic alterations in non-small cell lung cancer, namely EGFR, KRAS, BRAF, MET, and HER2 mutations or amplification, as well as ALK and ROS1 fusions. Furthermore, we investigated the predictive impact of these alterations on the outcomes of modern targeted therapies, their global prognostic significance, and their mutual interaction in cases of co-occurrence.</p>
                <p><strong>Cost:</strong> 0.015</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e213.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e213.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation prevalence in lung cancer across different ethnic populations, particularly comparing East Asian and non-Asian populations, including frequencies, patient characteristics, environmental factors, and proposed explanations for ethnic differences.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>EGFR mutations (NSCLC ethnic prevalence)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Epidermal Growth Factor Receptor (EGFR) sensitizing mutations in non-small cell lung cancer</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Sensitizing somatic mutations of the EGFR tyrosine kinase domain (primarily exon 19 deletions and exon 21 L858R) that are highly predictive of response to EGFR tyrosine kinase inhibitors and show large differences in prevalence across ethnic groups, being far more frequent in East Asian populations than in Western/Caucasian populations.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Molecular Epidemiology of the Main Druggable Genetic Alterations in Non-Small Cell Lung Cancer</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>The paper is a literature review summarizing multiple published cohorts and meta-analyses covering diverse geographic regions: East Asian cohorts (multiple studies cited, including reports of adenocarcinoma cohorts with EGFR rates up to 78% in some East Asian series), continental Asian populations (overall cited Asian prevalence 40-50%, 'up to 50%'), Western/Caucasian populations (reported 10-16% overall in Western/Caucasian populations), Middle East and African populations (systematic review/meta-analysis reporting frequencies slightly higher than Western but lower than Asian populations), and specific insular/Oceanic and Mediterranean series (reported ~12%). No single new primary cohort is produced in this paper; referenced cohort sizes vary by cited study (the review cites meta-analyses including >63,000 cases and individual large series).</td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_type</strong></td>
                            <td>Common (classic) sensitizing mutations: exon 19 in-frame deletions (Del19) and exon 21 L858R; Uncommon mutations: G719X (exon 18), S768I (exon 20), L861Q (exon 21), exon 20 insertions (Ins20), rarer exon 18â€“25 kinase domain duplications and fusion events; resistance mutation: T790M (gatekeeper, Thr790Met).</td>
                        </tr>
                        <tr>
                            <td><strong>mutation_frequency_asian</strong></td>
                            <td>Reported ranges in the review: up to 78% in adenocarcinomas in some East Asian reports; review-level summary frequently cited as ~40-50% in Asians (paper conclusion: 'up to 50% of cases in Asian populations').</td>
                        </tr>
                        <tr>
                            <td><strong>mutation_frequency_non_asian</strong></td>
                            <td>Reported ranges in the review: 10-16% in Western/Caucasian populations (overall); Middle East and African populations 'slightly higher' than Western but lower than Asian; Oceanic/insular Mediterranean populations reported around 12%.</td>
                        </tr>
                        <tr>
                            <td><strong>has_comparative_ethnic_data</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>patient_smoking_status</strong></td>
                            <td>EGFR mutations are strongly associated with never-smoker status; the review cites figures up to ~66.6% of EGFR-mutant cases in never-smokers and notes meta-analysis evidence (167 studies, >63,000 cases) that increasing smoking history (particularly >30 pack-years) is associated with decreased odds of EGFR mutation. The review also notes sex differences (higher frequency in females: cited up to 42% of females vs 14% of males with NSCLC harbor EGFR TK domain mutations). It further comments that the pattern of smoking-associated prevalence may differ by ethnicity (the review states that 'this is particularly true for Caucasian non-smokers, where the mutation prevalence seems to be relatively greater than in Asian non-smokers' in the context of how smoking history modifies odds).</td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_histology</strong></td>
                            <td>Predominantly lung adenocarcinoma (sensitizing EGFR mutations 'almost exclusively' observed in adenocarcinoma vs other histologies).</td>
                        </tr>
                        <tr>
                            <td><strong>environmental_factors</strong></td>
                            <td>Smoking is the primary environmental factor discussed (inverse association with EGFR mutations; pack-year dose effect). The review mentions other lung cancer environmental risk factors in general (secondhand smoke, mineral/metal dusts, radon, asbestos) but does not ascribe them specifically to driving ethnic differences in EGFR mutation rates; it also raises the possibility that changes in smoking patterns (e.g., increased lung cancer in younger women) do not fully explain ethnic differences.</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_factors</strong></td>
                            <td>The review cites the hypothesis that Asians may have an 'inherent non-environmental susceptibility' to development of EGFR mutations and refers to studies proposing alternative (likely genetic/ancestral) mechanisms, but it does not identify specific germline variants or polymorphisms; it calls for further genetic investigation.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanism</strong></td>
                            <td>The authors state the reasons are unclear and summarize proposed explanations from the literature: (1) inherent non-environmental (likely genetic/ancestral) susceptibility among Asian populations requiring alternative mechanisms for lung cancer development; (2) differential exposure to tobacco and other environmental carcinogens (smoking history) modifying mutation odds; (3) possible study/population selection differences and methodological detection issues. No definitive molecular mechanism explaining ethnic disparity is established in the review.</td>
                        </tr>
                        <tr>
                            <td><strong>odds_ratio_or_risk</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>confounding_factors</strong></td>
                            <td>Potential confounders discussed include differences in smoking prevalence and pack-years across ethnic groups, sex distribution (higher female prevalence), histologic subtype distribution (adenocarcinoma predominance), age at diagnosis, differences in screening and referral practices, laboratory/sample quality and mutation detection methods (older studies vs NGS), and study selection biases; the review emphasizes limitations of older epidemiological studies and heterogeneity across cohorts.</td>
                        </tr>
                        <tr>
                            <td><strong>key_findings</strong></td>
                            <td>The review's synthesis: EGFR sensitizing mutations are markedly more frequent in Asian populations (summarized as ~40-50% overall in Asians and up to 78% in some East Asian adenocarcinoma cohorts) compared with Western/Caucasian populations (10-16%); Middle Eastern and African frequencies are intermediate and Oceanic/insular Mediterranean populations lower (~12%). EGFR mutations are strongly associated with adenocarcinoma histology, female sex, and never-smoker status; smoking reduces odds of EGFR mutations (dose effect with pack-years). The underlying causes for ethnic differences remain unresolved, with hypotheses favoring inherent genetic susceptibility in Asians and the modifying role of environmental exposures and study biases; the authors call for larger, modern sequencing-based epidemiologic studies to clarify causes and frequencies.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>The prevalence of EGFR mutation in patients with non-small cell lung cancer: A systematic review and meta-analysis <em>(Rating: 2)</em></li>
                <li>EGFR mutation frequency in Middle East and African non-small cell lung cancer patients: A systematic review and meta-analysis <em>(Rating: 2)</em></li>
                <li>Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases <em>(Rating: 2)</em></li>
                <li>Emerging ethnic differences in lung cancer therapy <em>(Rating: 1)</em></li>
                <li>Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers <em>(Rating: 1)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>